1960P Differential induction of gene expression may explain differences in reported adverse event profiles between the FGFR-inhibitors derazantinib and erdafitinib: An analysis in safety relevant normal tissues from urothelial cancer (UC) patient-derived mouse xenograft (PDX) models
Publication
, Conference
McSheehy, P; Guo, J; Beebe, K; Eisner, JR; Anderson, S; Braun, S; Engelhardt, M; Kellenberger, L; Lane, H; Milburn, M
Published in: Annals of Oncology
September 2020
Duke Scholars
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2020
Volume
31
Start / End Page
S1103 / S1104
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
McSheehy, P., Guo, J., Beebe, K., Eisner, J. R., Anderson, S., Braun, S., … Milburn, M. (2020). 1960P Differential induction of gene expression may explain differences in reported adverse event profiles between the FGFR-inhibitors derazantinib and erdafitinib: An analysis in safety relevant normal tissues from urothelial cancer (UC) patient-derived mouse xenograft (PDX) models. In Annals of Oncology (Vol. 31, pp. S1103–S1104). Elsevier BV. https://doi.org/10.1016/j.annonc.2020.08.1352
McSheehy, P., J. Guo, K. Beebe, J. R. Eisner, S. Anderson, S. Braun, M. Engelhardt, L. Kellenberger, H. Lane, and M. Milburn. “1960P Differential induction of gene expression may explain differences in reported adverse event profiles between the FGFR-inhibitors derazantinib and erdafitinib: An analysis in safety relevant normal tissues from urothelial cancer (UC) patient-derived mouse xenograft (PDX) models.” In Annals of Oncology, 31:S1103–4. Elsevier BV, 2020. https://doi.org/10.1016/j.annonc.2020.08.1352.
McSheehy P, Guo J, Beebe K, Eisner JR, Anderson S, Braun S, et al. 1960P Differential induction of gene expression may explain differences in reported adverse event profiles between the FGFR-inhibitors derazantinib and erdafitinib: An analysis in safety relevant normal tissues from urothelial cancer (UC) patient-derived mouse xenograft (PDX) models. In: Annals of Oncology. Elsevier BV; 2020. p. S1103–4.
McSheehy, P., et al. “1960P Differential induction of gene expression may explain differences in reported adverse event profiles between the FGFR-inhibitors derazantinib and erdafitinib: An analysis in safety relevant normal tissues from urothelial cancer (UC) patient-derived mouse xenograft (PDX) models.” Annals of Oncology, vol. 31, Elsevier BV, 2020, pp. S1103–04. Crossref, doi:10.1016/j.annonc.2020.08.1352.
McSheehy P, Guo J, Beebe K, Eisner JR, Anderson S, Braun S, Engelhardt M, Kellenberger L, Lane H, Milburn M. 1960P Differential induction of gene expression may explain differences in reported adverse event profiles between the FGFR-inhibitors derazantinib and erdafitinib: An analysis in safety relevant normal tissues from urothelial cancer (UC) patient-derived mouse xenograft (PDX) models. Annals of Oncology. Elsevier BV; 2020. p. S1103–S1104.
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2020
Volume
31
Start / End Page
S1103 / S1104
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis